This page shows the latest Tyvyt news and features for those working in and with pharma, biotech and healthcare.
Although median overall survival (OS) was not reached in both groups, OS showed an improvement favouring the Tyvyt combination. ... Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications.
Also included on the updated list is the PD-1 inhibitor Tyvyt (sintilimab) – jointly developed by Innovent Biologics and Eli Lilly – for the treatment of relapsed/refractory Hodgkin’s lymphoma. ... If approved, it could directly rival
Chinese biotech Innovent is in the final stages of preparing to launch its cancer immunotherapy Tyvyt in its home market. ... The approval of Tyvyt…enables Innovent's delivery on its social responsibility to offer innovative drugs affordable to
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...